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2 
Abstract  40 
To further resolve the genetic architecture of the inflammatory bowel diseases, ulcerative 41 
colitis and Crohn’s disease, we sequenced the whole genomes of 4,280 patients at low 42 
coverage, and compared them to 3,652 previously sequenced population controls across 73.5 43 
million variants. We then imputed from these sequences into new and existing GWAS cohorts, 44 
and tested for association at ~12 million variants in a total of 16,432 cases and 18,843 controls. 45 
We discovered a 0.6% frequency missense variant in ADCY7 that doubles risk of ulcerative 46 
colitis. Despite good statistical power, we did not identify any other new low-frequency risk 47 
variants, and found that such variants explained little heritability.  We detected a burden of 48 
very rare, damaging missense variants in known Crohn’s disease risk genes, suggesting that 49 
more comprehensive sequencing studies will continue to improve our understanding of the 50 
biology of complex diseases. 51 
Introduction  52 
Crohn’s disease and ulcerative colitis, the two common forms of inflammatory bowel disease (IBD), 53 
are chronic and debilitating diseases of the gastrointestinal tract that result from the interaction of 54 
environmental factors, including the intestinal microbiota, with the host immune system in genetically 55 
susceptible individuals. Genome-wide association studies (GWAS) have identified 215 IBD associated 56 
loci that have substantially expanded our understanding of the biology underlying these diseases1–8. 57 
The correlation between nearby common variants in human populations underpins the success of the 58 
GWAS approach, but this also makes it difficult to infer precisely which variant is causal, the 59 
molecular consequence of that variant, and often even which gene is perturbed. Rare variants, which 60 
plausibly have larger effect sizes, can be more straightforward to interpret mechanistically because 61 
they are correlated with fewer nearby variants. However, it remains to be seen how much of the 62 
heritability9 of complex diseases is explained by rare variants. Well powered studies of rare variation 63 
in IBD thus offer an opportunity to better understand both the biological and genetic architecture of an 64 
exemplar complex disease.  65 
The marked drop in the cost of DNA sequencing has enabled rare variants to be captured at scale, 66 
but there remains a fundamental design question regarding how to most effectively distribute short 67 
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sequence reads in two dimensions: across the genome, and across individuals. The most important 68 
determinant of GWAS success has been the ability to analyze tens of thousands of individuals, and 69 
detecting rare variant associations will require even larger sample sizes10. Early IBD sequencing 70 
studies concentrated on the protein coding sequence in GWAS-implicated loci11–14 , which can be 71 
naturally extended to the entire exome15–17. However, coding variation explains at most 20% of the 72 
common variant associations in IBD GWAS loci18, and others have more generally observed19 that the 73 
substantial majority of complex disease associated variants lie in non-coding, presumed regulatory, 74 
regions of the genome. Low coverage whole genome sequencing has been proposed20 as an 75 
alternative approach that captures this important non-coding variation, while being cheap enough to 76 
enable thousands of individuals to be sequenced. As expected, this approach has proven valuable in 77 
exploring rarer variants than those accessible in GWAS21,22, but is not ideally suited to the analysis of 78 
extremely rare variants. 79 
Our aim was to determine whether low coverage whole genome sequencing provides an efficient 80 
means of interrogating these low frequency variants, and how much they contribute to IBD 81 
susceptibility. We present an analysis of the whole genome sequences of 4,280 IBD patients, and 82 
3,652 population controls sequenced as part of the UK10K project23, both via direct comparison of 83 
sequenced individuals and as the basis for an imputation panel in an expanded UK IBD GWAS 84 
cohort. This study allows us to examine, on a genome-wide scale, the role of low-frequency (0.1%≤ 85 
MAF < 5%) and rare (MAF < 0.1%) variants in IBD risk. 86 
Results     87 
Whole genome sequencing of 7,932 individuals   88 
Following quality control (Supplementary Note and Supplementary Table 1-2), whole genome 89 
sequences of 2,513 Crohn’s disease patients (median coverage 4x) and 1,767 ulcerative colitis 90 
patients (2x) were jointly analyzed with 3,652 population controls (7x) sequenced as part of the 91 
UK10K project23 (Figure 1). We discovered 87 million autosomal single nucleotide variants (SNVs) 92 
and 7 million short indels (Supplementary Note and Supplementary Table 3). We then applied support 93 
4 
vector machines for SNVs and GATK VQSR24 for indels to distinguish true sites of genetic variation 94 
from sequencing artifacts  (Figure 1, Supplementary Note). We called genotypes jointly across all 95 
samples at the remaining sites, followed by genotype refinement using the BEAGLE imputation 96 
software25. This procedure leverages information across multiple individuals and uses the correlation 97 
between nearby variants to produce high quality data from relatively low sequencing depth. We noted 98 
that genotype refinement was locally affected by poor quality sites that failed further quality control 99 
analyses, so we ran BEAGLE a second time after these exclusions, yielding a set of 73.5 million high 100 
quality sites (Supplementary Note, Supplementary Figure 1-3 and Supplementary Table 4). Over 99% 101 
of common SNVs (MAF ≥ 5%) were also found in 1000 Genomes Project Phase 3 Europeans, 102 
indicating high specificity. Among rarer variants, 54.6 million were not seen in 1000 Genomes, 103 
demonstrating the value of directly sequencing the IBD cases and UK population controls 104 
(Supplementary Table 5, Supplementary Figure 3).  105 
We also discovered 180,000 deletions, duplications and multiallelic copy number variants (CNVs) 106 
using GenomeStrip 2.026, but noted large differences in sensitivity between the three different sample 107 
sets (Supplementary Figure 4). Following quality control (Supplementary Note), including removal of 108 
CNVs with length < 60 kilobases, we observed an approximately equal number of variants in cases 109 
and controls, but retained only 1,475 CNVs. However, we still note a genome-wide excess of rare 110 
CNVs in controls (P=0.002), indicating that even after stringent filtering the data remains too noisy for 111 
meaningful conclusions to be drawn. We suggest that high coverage whole genome sequencing 112 
balanced in cases and controls will be required to evaluate the contribution of rare CNVs to IBD risk. 113 
We individually tested 13 million SNVs and small indels with MAF ≥0.1% for association, and 114 
observed that we had successfully eliminated systematic differences due to sequence depth (1000_UC 115 
= 1.05,  1000_CD = 1.04, 1000_IBD =1.06, Supplementary Figure 5), while still retaining power to detect 116 
known associations. While we estimate that this stringent quality control produced well calibrated 117 
association test statistics for more than 99% of sites, this analysis yielded many extremely significant 118 
p-values at SNPs outside of known loci (e.g. ~7,000 with p < 10-15), 95% of which had an allele 119 
frequency below 5%. In contrast to GWAS, where routine procedures almost completely eliminate 120 
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false positive associations, the heterogeneity of our sequencing depths makes it challenging to 121 
discern true associations from these data alone. 122 
 123 
Imputation into GWAS  124 
As noted by a previous study of type 2 diabetes27 with a similar design, our WGS dataset alone is not 125 
well powered to identify new associations, even if all samples were sequenced at the same depth. We 126 
therefore built a phased reference panel of 10,971 individuals from our low coverage whole genome 127 
sequences and 1000 Genomes Phase 3 haplotypes (Supplementary Note), in order to use imputation 128 
to leverage IBD GWAS to increase our power. Previous data have shown that such expanded 129 
reference panels significantly improve imputation accuracy of low-frequency variants28. We next 130 
generated a new UK IBD GWAS dataset by genotyping 8,860 IBD patients without previous GWAS 131 
data and combining them with 9,495 UK controls from the Understanding Society project 132 
(www.understandingsociety.ac.uk), all genotyped using the Illumina HumanCoreExome v12 chip. We 133 
then added previous UK IBD GWAS samples that did not overlap with those in our sequencing 134 
dataset29,30. Finally, we imputed all of these samples using the PBWT31 software and the reference 135 
panel described above, and combined these imputed genomes with our sequenced genomes to 136 
create a final dataset of 16,267 IBD cases and 18,843 UK population controls (Supplementary Table 137 
6).  138 
This imputation produced high quality genotypes at 12 million variants that passed typical GWAS 139 
quality control (Supplementary Note), and represented more than 90% of sites with MAF >0.1% that 140 
we could directly test in our sequences. Compared to the most recent meta-analysis by the 141 
International IBD Genetics Consortium32, which used a reference panel almost ten times smaller than 142 
ours, we tested an additional 2.5 million variants for association to IBD Because our GWAS cases and 143 
controls were genotyped using the same arrays, they should be not be differentially affected by the 144 
variation in sequencing depths in the reference panel, and thus not susceptible to the artifacts 145 
observed in the sequence-only analysis. Indeed, compared to the thousands of false-positive 146 
associations present in the sequence-only analysis, the imputation based meta-analysis revealed only 147 
four previously undescribed genome-wide significant IBD associations. Three of these had MAF > 148 
6 
10%, so we carried them forward to a meta-analysis of our data and published IBD GWAS summary 149 
statistics33. 150 
  151 
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Asp439Glu in ADCY7 doubles risk of ulcerative colitis 152 
The fourth new association (P = 9x10-12) was a 0.6% missense variant (p.Asp439Glu, rs78534766) in 153 
ADCY7 that doubles risk of ulcerative colitis (OR=2.19, 95% CI =1.75-2.74), and is strongly predicted 154 
to alter protein function (SIFT = 0, PolyPhen = 1, MutationTaster = 1). This variant was associated 155 
(p=1x10-6) in a subset of directly genotyped individuals, suggesting the signal was unlikely to be 156 
driven by imputation errors. To further validate it we genotyped (Online Methods) an additional 450 157 
ulcerative colitis cases and 3,905 controls (p=0.0009) and looked it up in 982 ulcerative colitis cases 158 
and 136,464 controls from the UK Biobank (p=0.0189). A meta-analysis of all three directly genotyped 159 
datasets showed genome-wide significant association (p=1.6x10-9), no evidence for heterogeneity 160 
(p=0.19) and clean cluster plots (Supplementary Table 7, Supplementary Figure 6). A previous report 161 
described an association between an intronic variant in this gene and Crohn’s disease34, but our 162 
signal at this variant (P = 2.9x10-7) vanishes after conditioning on the nearby associations at NOD2, 163 
(conditional P = 0.82). By contrast, we observed that p.Asp439Glu shows nominal association with 164 
Crohn’s disease after conditioning on NOD2 (P = 7.5x10-5, OR=1.40), while the significant signal 165 
remains for ulcerative colitis (Figure 2). Thus, one of the largest effect single alleles associated with 166 
ulcerative colitis lies, apparently coincidentally, only 300 kilobases away from a region of the genome 167 
that contains multiple large effect Crohn’s disease risk alleles (Figure 2). 168 
The protein encoded by ADCY7, adenylate cyclase 7, is one of a family of ten enzymes that convert 169 
ATP to the ubiquitous second messenger cAMP. Each has distinct tissue-specific expression 170 
patterns, with ADCY7 being expressed in haemopoietic cells. Here, cAMP modulates innate and 171 
adaptive immune functions, including the inhibition of the pro-inflammatory cytokine TNFα, itself the 172 
target of the most potent current therapy in IBD35. Indeed, myeloid-specific Adcy7 knockout mice 173 
(constitutive knockouts die in utero) show higher stimulus-induced production of TNFα by 174 
macrophages, impairment in B cell function and T cell memory, an increased susceptibility to LPS-175 
induced endotoxic shock, and a prolonged inflammatory response36,37. In human THP-1 (monocyte-176 
like) cells, siRNA knockdown of ADCY7 also leads to increased TNFα production.38 p.Asp439Glu 177 
affects a highly conserved amino acid in a long cytoplasmic domain immediately downstream of the 178 
first of two active sites and may affect the assembly of the active enzyme through misalignment of the 179 
active sites39. 180 
8 
Low-frequency variation makes a minimal contribution to IBD susceptibility 181 
The associated variant in ADCY7 represents precisely the class of variant that our study design was 182 
intended to probe: below 1% MAF, OR ~2, and difficult to impute (only 1 copy of the non-reference 183 
allele was observed in the Phase 1 1000 Genomes, and INFO=0.7 when imputing33 from Phase 3), 184 
making it notable as our single discovery of this type. We had 66% power to detect that association, 185 
and reasonable power even for more difficult scenarios (e.g. 29% for 0.2% MAF and OR=2, or 11% 186 
for 0.5% MAF and OR=1.5). As noted by others40, heritability estimates for low frequency variants as 187 
a class are exquisitely sensitive to potential bias from technical and population differences. We 188 
therefore analyzed only the imputed GWAS samples to eliminate the effect of differential sequencing 189 
depth, and applied a more stringent SNP and sample quality control (Supplementary Note and 190 
Supplementary Figure 7). We used the restricted maximum likelihood (REML) method implemented in 191 
GCTA41 and estimated that autosomal SNPs with MAF > 0.1% explain 28.4% (s.e. 0.016) and 21.1% 192 
(s.e. 0.012) of the variation in liability for Crohn’s and ulcerative colitis, respectively. Despite SNPs 193 
with MAF < 1% representing approximately 81% of the variants included in this analysis, they 194 
explained just 1.5% of the variation in liability. While these results are underestimates due to 195 
limitations of our data and the REML approach, it seems very unlikely that a large fraction of IBD risk 196 
is captured by variants like ADCY7 p.Asp439Glu. Thus, our discovery of ADCY7 actually serves as an 197 
illustrative exception to a series of broader observations42  that low-frequency, high-risk variants are 198 
unlikely to be important contributors to IBD risk.  199 
The role of rare variation in IBD risk 200 
Our low coverage sequencing approach does not perfectly capture very rare and private variants 201 
because the cross-sample genotype refinement adds little information at sites where nearly all 202 
individuals are homozygous for the major allele. Similarly, these variants are difficult to impute from 203 
GWAS data: even using a panel of more than 32,000 individuals offers little imputation accuracy 204 
below 0.1% MAF28. Thus, while our sequence dataset was not designed to study rare variants, it is 205 
the largest to date in IBD, and has sufficient specificity and sensitivity to warrant further investigation 206 
(Supplementary Figure 8). Because enormous sample sizes would be required to implicate any single 207 
variant, we used a standard approach from exome sequencing43, where variants of a particular 208 
functional class are aggregated into a gene-level test. We extended Derkach et al’s Robust Variance 209 
9 
Score statistic44 to account for our sequencing depth heterogeneity, because existing rare variant 210 
burden methods gave systematically inflated test statistics. 211 
For each of 18,670 genes, we tested for a differential burden of rare (MAF ≤ 0.5% in controls, 212 
excluding singletons) functional or predicted damaging coding variation in our sequenced cases and 213 
controls (Online Methods, Supplementary Table 8-9). We detected a significant burden of damaging 214 
rare variants in the well-known Crohn’s disease risk gene NOD2 (Pfunctional = 1x10−7, Supplementary 215 
Figure 9), which was independent of the known low-frequency NOD2 risk variants (Online Methods). 216 
We noted that the additional variants (Figure 3) that contribute to this signal explain only 0.13% of the 217 
variance in disease liability, compared to 1.15% for the previously known variants11, underscoring the 218 
fact that very rare variants cannot account for much population variability in risk. 219 
Some genes implicated by IBD GWAS had suggestive p-values, but did not reach exome-wide 220 
significance (P=5x10-7, Supplementary Table 10), so we combined individual gene results into two 221 
sets: (i) 20 genes that had been confidently implicated in IBD risk by fine-mapping or functional data, 222 
and (ii) 63 additional genes highlighted by less precise GWAS annotations (Supplementary Note, 223 
Supplementary Table 11). We tested these two sets (after excluding NOD2, which otherwise 224 
dominates the test) using an enrichment procedure43 that allows for differing direction of effect 225 
between the constituent genes (Supplementary Note, Supplementary Table 12). We found a burden 226 
in the twelve confidently implicated Crohn’s disease genes that contained at least one damaging 227 
missense variant (Pdamaging = 0.0045). By contrast, we saw no signal in the second, more generic set 228 
of genes (P=0.94, Figure 4, Table 1). 229 
We extended this approach to evaluate rare regulatory variation, using enhancer regions described by 230 
the FANTOM5 project (Supplementary Table 13). Within each robustly defined enhancer45, we tested 231 
all observed rare variants, as well as the subset predicted to disrupt or create a transcription factor 232 
binding motif18. We combined  groups of enhancers with cell- and/or tissue-type specific expression, 233 
in order to improve power in an analogous fashion to the gene set tests above. However, none of 234 
these tissue or cell specific enhancer sets had a significant burden of rare variation after correction for 235 
multiple testing (Supplementary Table 14). 236 
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Discussion 238 
We investigated the role of low frequency variants of intermediate effect in IBD risk through a 239 
combination of low-coverage whole genome sequencing and imputation into GWAS data (Figure 5). 240 
We discovered an association to a low frequency missense variant in ADCY7, which represents one 241 
of the strongest ulcerative colitis risk alleles outside of the major histocompatibility complex. The most 242 
straightforward mechanistic interpretation of this association is that loss-of-function of ADCY7 reduces 243 
production of cAMP, leading to an excessive inflammatory response that predisposes to IBD. 244 
Previous evidence suggested that general cAMP-elevating agents that act on multiple adenylate 245 
cyclases might, in fact, worsen IBD46. While members of the adenylate cyclase family have been 246 
considered potential targets in other contexts 39, specific upregulation of ADCY7 has not yet been 247 
attempted, raising the intriguing possibility that altering cAMP signalling in a leukocyte-specific way 248 
might offer therapeutic benefit in IBD. 249 
In order to maximize the number of IBD patients we could sequence, and thus our power to detect 250 
association, we sequenced our cases at lower depth than the controls available to us via managed 251 
access. While joint and careful analysis largely overcame the bias this introduces, this is just one 252 
example of the complexities associated with combining sequencing data from different studies. Such 253 
challenges are not just restricted to low coverage whole-genome sequencing designs; variable 254 
pulldown technology and sequencing depth in the 60,000 exomes in the Exome Aggregation 255 
Consortium47 necessitated a simultaneous analysis of such analytical complexity and computational 256 
intensity that it would be prohibitive at all but a handful of research centers. Therefore, if rare variant 257 
association studies are to be as successful as those for common variants, computationally efficient 258 
methods and accepted standards for combining sequence datasets need to be developed.  259 
We have participated in one such joint analysis by contributing to the Haplotype Reference 260 
Consortium28 (HRC), which has collected WGS data from more than 32,000 individuals into a 261 
reference panel that allows accurate imputation of low-frequency and common variants. Indeed, 262 
imputation into GWAS from the HRC is as accurate as low-coverage sequencing at allele frequencies 263 
as low as 0.05%28, so by far the most effective way to discover complex disease associations to 264 
variants in this range is to re-analyze the huge quantities of existing GWAS data with improved 265 
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imputation. While projects like ours have provided wider public benefit through the HRC, there is little 266 
need for future low-coverage whole genome sequencing projects in complex disease.  267 
Despite our study being specifically designed to interrogate both coding and non-coding variation, our 268 
sole new association was a missense variant. This is perhaps unsurprising, as the only previously 269 
identified IBD risk variants with similar frequencies and odds ratios are protein-altering changes to 270 
NOD2, IL23R and CARD9. More generally, the alleles with largest effect sizes at any given frequency 271 
tend to be coding18, and are therefore the first to be discovered when new technologies expand the 272 
frequency spectrum of genetic association studies. This pattern is further reinforced by the contrast 273 
between the tantalizing evidence we found for a burden of very rare coding variants in previously 274 
implicated IBD genes and the absence of any signal across the enhancer regions we tested. This 275 
distinction emphasizes how dramatically better we can distinguish likely functional from neutral 276 
variants in coding compared to non-coding sequence. For example, if we include all rare coding 277 
variants (MAF ≤ 0.5% in controls, N=136) in IBD genes the P-value is 0.2291, compared to P=0.0045 278 
when using the subset of 54 coding variants with CADD ≥ 21. Therefore, the identification of rare 279 
variant burdens in the non-coding genome will require not only tens of thousands of samples to be 280 
sequenced, but also much better discrimination between functional and neutral variants in regulatory 281 
regions. 282 
Nonetheless, it is likely that rare variants play an important role in IBD risk, and that many such alleles 283 
are regulatory, as is the case for common risk variants. The ADCY7 association offers a direct window 284 
on a new IBD mechanism, but would probably eventually have been discovered through HRC 285 
imputation in existing GWAS samples, and is a relatively meager return compared to the number of 286 
loci discovered more simply by increasing GWAS sample size33. Making real progress on rare variant 287 
association studies will require much larger numbers of deep exomes or whole genomes, especially if 288 
“ultra-rare” variants are as important in IBD as they are in, for example, schizophrenia48, . 289 
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Extrapolating10 for IL23R, the IBD gene with the most significant coding burden (p=0.0005)  after 290 
NOD2, we would require roughly 20,000 cases to reach genome-wide significance; as we noted 291 
above the challenge is even greater for non-coding regions where functional variants cannot currently 292 
be distinguished from neutral. Together, our discoveries suggest that a combination of continued 293 
GWAS coupled to new imputation reference panels, and large scale deep sequencing studies will be 294 
needed to complete our understanding of the genetic basis of complex diseases. 295 
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Figure Legends 432 
Figure 1. Overview of our study. Variants were called from raw sequence reads in three groups of 433 
samples, and jointly filtered using support vector machines. The resulting genotypes were refined 434 
using BEAGLE and incorporated into the reference panel for a GWAS-imputation based meta-435 
analysis, which discovered a low frequency association in ADCY7. A separate gene-based analysis 436 
identified a burden of rare damaging variants in certain known Crohn’s disease genes. 437 
Figure 2. Association analysis for the NOD2/ADCY7 region in chromosome 16. Results from the 438 
single variant association analysis are presented in gray, and results after conditioning on seven 439 
known NOD2 risk variants in blue. Results for Crohn’s disease (CD) are shown in the top half, and 440 
ulcerative colitis (UC) in the bottom half. The dashed red lines indicate genome-wide significance, at α 441 
= 5x10-8.  442 
Figure 3. Associations between NOD2 and Crohn’s disease. Each point represents the 443 
contribution of an individual variant to our NOD2 burden test. Three common variants (rs2066844, 444 
rs2066845, rs2066847) are shown for scale, and the six rare variants identified by targeted 445 
sequencing are starred. Exonic regions (not to scale) are marked in blue, with their corresponding 446 
protein domains highlighted. 447 
Figure 4. Burden of rare damaging variants in Crohn’s disease. Each point represents a gene in 448 
our confidently implicated (green) or generically implicated (blue) gene sets. Genes are ranked on the 449 
x-axis from most enriched in cases to most enriched in controls, and position on the y-axis represents 450 
significance. The purple shaded region indicates where 75% of all genes tested lie. Our burden signal 451 
is driven by a mixture of genes where rare variants are risk increasing (e.g. NOD2) and risk 452 
decreasing (IL23R). 453 
Figure 5. Relative power of this study compared to previous GWAS. The black line shows the 454 
path through frequency-odds ratio space where the latest IIBDGC meta-analysis had 80% power. The 455 
purple line (imputed GWAS) and green line (sequencing) shows the same for this study. The earlier 456 
study had more samples but restricted their analysis to MAF > 1%. Purple density and points show 457 
known GWAS loci, with our novel ADCY7 association (p.Asp439Glu) highlighted as a star. Green 458 
points show a subset of our sequenced NOD2 rare variants, and the green star shows their equivalent 459 
position when tested by gene burden, rather than individually.  460 
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Tables 461 
Table 1. Burden of rare, predicted damaging (CADD ≥ 21) coding variation in IBD gene sets.  462 
 463 
Gene set Constituents Phenotype P-value 
NOD2 NOD2 CD 4.00 x 10-07 
Other IBD genes 
implicated by causal 
coding or eQTL variants 
(genes in brackets had 
zero contributing rare 
variants) 
CARD9, FCGR2A, IFIH1, IL23R, 
MST1, (SMAD3), TYK2, (IL10), 
IL18RAP, (ITGAL), NXPE1, 
TNFSF8 
UC 0.46153 
ATG16L1, CARD9, CD6, FCGR2A, 
FUT2, IL23R, MST1, (NOD2), 
PTPN22, (SMAD3), TYK2, ERAP2, 
(IL10), IL18RAP, (IL2RA), 
(SP140), TNFSF8 
CD 0.00448 
CARD9, FCGR2A, IL23R, MST1, 
(SMAD3), TYK2, (IL10), IL18RAP, 
TNFSF8 
IBD 0.00261 
Other IBD GWAS genes 
Genes implicated by two or 
more candidate gene 





  464 
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Online Methods    465 
Preparation of genome-wide genetic data 466 
Sample ascertainment and sequencing. British IBD cases, diagnosed using accepted endoscopic, 467 
histopathological and radiological criteria, were sequenced to low depth (2-4x) using Illumina HiSeq 468 
paired-end sequencing. Population controls, also sequenced to low depth (7x) using the same 469 
protocol, were obtained from the UK10K project. Supplementary Table 2 provides details on sample 470 
numbers and quality control filters. Case sequence data was aligned to the human reference used in 471 
Phase II of the 1000 Genomes project49. Control data was aligned to an earlier human reference 472 
(1000 Genomes Phase I)50, and then updated to the same reference as the cases using 473 
BridgeBuilder, a tool we developed (Supplementary Note). 474 
Genotype calling and quality control. Variants were joint called across 8,424 samples, using samtools 475 
and bcftools for SNVs and INDELs, and GenomeSTRiP for copy number variants. Copy number 476 
variants were filtered using standard GenomeSTRiP quality metrics as described in the 477 
Supplementary Note. SNVs were filtered using support vector machines (SVMs) trained on variant 478 
quality statistics output from samtools. Each variant was required to pass with a minimum score of 479 
0.01 from at least two out of five independent SVM models. Indels were filtered using GATK VQSR, 480 
with a truth sensitivity threshold of 97% (VQSLOD score of 1.0659).  481 
Genotype refinement and further quality control. Following initial SNV and INDEL quality control, 482 
genotypes at all passing sites were refined via BEAGLE25. Variants were then filtered again to remove 483 
those showing significant evidence of deviation from Hardy-Weinberg equilibrium (HWE) in controls 484 
(PHWE<1x10-7), a significant frequency difference (P < 1x10-3) in samples sequenced at the Wellcome 485 
Trust Sanger Institute versus the Beijing Genomics Institute, >10% missing genotypes following 486 
refinement (posterior probability < 0.9), SNPs within three base pairs of an INDEL, and allow only one 487 
INDEL to pass when clusters of INDELs were separated by two or fewer base pairs. Following these 488 
exclusions, a second round of genotype refinement was performed. Sample quality control was then 489 
applied to remove samples with an excessive heterozygosity rate (ߤ ± 3.5ߪ), duplicated or related 490 
individuals, and individuals of non-European ancestry (Supplementary Note and Supplementary 491 
Figure 10).  492 
22 
Novel GWAS samples. A further 11,768 British IBD cases and 10,484 population control samples 493 
were genotyped on the Human Core Exome v12 chip. Detailed information on ascertainment, 494 
genotyping and quality control are described elsewhere33. 495 
Existing GWAS cohorts. 1,748 Crohn’s disease cases and 2,936 population controls genotyped on 496 
the Affymetrix 500K chip, together with 2,361 ulcerative colitis cases and 5,417 population controls 497 
genotyped on the Affymetrix 6.0 array, were obtained from the Wellcome Trust Case Control 498 
Consortium (WTCCC)29,30. Both datasets were converted to build 37 using liftOver51. 499 
Imputation. The whole genome sequences described above were combined with 2504 samples from 500 
the Phase 3 v5 release of the 1000 Genomes project (2013-05-02 sequence freeze) to create a 501 
phased imputation reference panel enriched in IBD-associated variants. We used PBWT52 to impute 502 
from this reference panel (114.2 million total variants) into the three GWAS panels described above, 503 
after removing overlapping samples. This results in imputed whole genome sequences for 11,987 504 
cases and 15,189 controls (Supplementary Table 6). 505 
Common and low-frequency variation association testing 506 
Association testing and meta-analysis. We tested for association to ulcerative colitis, Crohn’s disease 507 
and IBD separately within the sequenced samples and three imputed GWAS panels using SNPTEST 508 
v2.5, performing an additive frequentist association test conditioned on the first ten principal 509 
components for each cohort (calculated after exclusion of the MHC region). We filtered out variants 510 
with MAF < 0.1%, INFO < 0.4, or strong evidence for deviations from HWE in controls (pHWE<1x10-7), 511 
and then used METAL (release 2011-03-05)53 to perform a standard error weighted meta-analysis of 512 
all four cohorts. Only sites for which all cohorts passed our quality control filters were included in our 513 
meta-analysis.  514 
Quality control. The output of the fixed-effects meta-analysis was further filtered, and sites with high 515 
evidence for heterogeneity (I2>0.90) were discarded. In addition, we discarded all genome-wide 516 
significant variants for which the meta-analysis p-value was not lower than all of the cohort-specific p-517 
values. Finally, and in order to minimise the false positive associations due to mis-imputation, sites 518 
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which did not have an info score ≥ 0.8 in at least three of the four datasets (two of the three for 519 
Crohn’s disease and ulcerative colitis) were removed. 520 
Locus definition. A linkage disequilibrium (LD) window was calculated for every genome-wide 521 
significant variant in any of the three traits (Crohn’s disease, ulcerative colitis, IBD), defined by the 522 
left-most and right-most variants that are correlated with the main variant with an r2 of 0.6 or more. 523 
The LD was calculated in the GBR and CEU samples from the 1000 Genomes Phase 3, release v5 524 
(based on 20130502 sequence freeze and alignments). Loci with overlapping LD windows, as well as 525 
loci whose lead variants were separated by 500kb or less, were subsequently merged, and the variant 526 
with the strongest evidence of being associated was kept as the lead variant for each merged locus. 527 
This process was conducted separately for each trait. A locus was annotated as known when there 528 
was at least one variant in it that was previously reported (Supplementary Table 15) to be of genome-529 
wide significance (irrespective of the LD between that variant and the most associated variants in the 530 
locus), and as novel otherwise. 531 
Conditional analysis. Conditional analyses were conducted using SNPTEST 2.5 54, as for the single 532 
variant association analysis. P-values were derived using the score test (default in SNPTEST v2.5). In 533 
order to fully capture the NOD2 signal when investigating the remaining signal in the region, we 534 
conditioned on seven variants which are known to be associated: rs2066844, rs2066845, rs2066847, 535 
rs72796367, rs2357623, rs184788345, and rs104895444.  536 
Replication of the ADCY7 association. Following quality control33, an additional 450 UK ulcerative 537 
colitis cases and 3905 population controls (Dupuytren’s contracture cases), genotyped using the 538 
Illumina Human Core Exome array v12, were available for replication. An additional 982 ulcerative 539 
colitis cases and 136,464 controls from the UK Biobank, genotyped on either the UK Biobank Axiom 540 
or UK BiLEVE array, formed a second replication cohort . Quality control of the UK biobank data was 541 
performed as previously described (http://biobank.ctsu.ox.ac.uk/crystal/docs/genotyping_qc.pdf), and 542 
non-British or Irish individuals were excluded from further analysis. Cases were defined as those with 543 
self-reported ulcerative colitis or an ICD10 code of K51 in their Hospital Episode Statistics (HES) 544 
record. Controls were defined as those individuals without a self-diagnosis or hospital record of 545 
ulcerative colitis or Crohn’s disease (HES = K50). Logistic regression conditional on 10 principal 546 
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components test was carried out in both replication cohorts. We used METAL (release 2011-03-05)53 547 
to perform a standard error weighted meta-analysis of all three directly genotyped cohorts. 548 
Heritability explained. The SNP heritability analysis was performed on the dichotomous case-control 549 
phenotype using constrained REML in GCTA41 with a prevalence of 0.005 and 0.0025 for Crohn’s 550 
disease and ulcerative colitis respectively. Hence, all reported values of h2g are on the underlying 551 
liability scale. To further eliminate spurious associations we computed genetic relationship matrices 552 
(GRMs) restricted to all variants with MAF ≥ 0.1%, imputation r2 ≥ 0.6, missing rate ≤ 1% and Hardy-553 
Weinberg equilibrium P-value ≤ 1x10-7 in controls for each GWAS cohort. We further checked the 554 
reliability and robustness of our estimates by performing a joint analysis across all autosomes, a joint 555 
analysis between common (MAF≥1%) and rare variants (0.1%≤MAF<1%), and LD-adjusted analysis 556 
using LDAK55 (Supplementary Note, Supplementary Table 16, Supplementary Figure 7). 557 
Rare variation association testing 558 
Additional variant quality control. Additional site filtering was undertaken, as rare variant association 559 
studies are more susceptible to differences in read depth between cases and controls (Supplementary 560 
Figure 11). This included removing singletons, as well as sites with: missingness rate > 0.9 when 561 
calculated using genotype probabilities estimated from the samtools genotype quality (GQ) field; low 562 
confidence observations comprising ≥ 1% of non-missing data, or; INFO < 0.6 in the appropriate 563 
cohorts.  564 
Association testing. Individual gene and enhancer burden tests were performed using an extension of 565 
the Robust Variance Score statistic44 (Supplementary Note), to adjust for the systematic coverage 566 
bias between cases and controls. This required the estimation of genotype probabilities directly from 567 
25 
samtools (using the genotype quality score), as genotype refinement using imputation results in poorly 568 
calibrated probabilities at rare sites. Burden tests were performed across sites with a MAF ≤ 0.5% in 569 
controls and within genes defined by Ensembl, or enhancers as based on its inclusion in the 570 
FANTOM5 ‘robustly-defined’ enhancer set45. For each gene, two sets of burden tests were performed: 571 
all functional coding variants and all predicted damaging (CADD ≥ 21) functional coding variants 572 
(Supplementary Table 8). For each enhancer, burden tests were repeated to include all variants 573 
falling within the region, and just the subset predicted to disrupt or create a transcription factor binding 574 
motif (Supplementary Note).  575 
NOD2 independence testing. We evaluated the independence of the rare NOD2 signal from the 576 
known common coding variants in this gene (rs2066844, rs2066845, and rs2066847). Individuals with 577 
a minor allele at any of these sites were assigned to one group, and those with reference genotypes 578 
to another. Burden testing was performed for this new phenotype in both variant sets that contained a 579 
significant signal in Crohn’s disease vs controls. 580 
Set definition. The individual burden test statistic was extended to test across sets of genes and 581 
enhancers using an approach based on the SMP method43, whereby the test statistic for a given set is 582 
evaluated against the statistics from the complete set (e.g. all genes), to account for residual case-583 
control coverage bias. The sets of genes confidently associated with IBD risk were defined based on 584 
implication of specific genes in ulcerative colitis, Crohn’s disease or IBD risk through fine-mapping, 585 
eQTL and targeted sequencing studies (Supplementary Table 11). The broader set of IBD genes was 586 
defined as any remaining genes implicated by two or more candidate gene approaches in Jostins et al 587 
(2012)56. Enhancer sets were defined as those showing positive differential expression in each of 69 588 
cell types and 41 tissues, according to Andersson et al45 (Supplementary Table 17).  589 
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